Pfizer heads into earnings with a lower Goldman Sachs price target as investors weigh patent risks, Covid declines, and ...

The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

Pfizer (PFE) recently reported a revenue decline tied to weaker COVID product sales and a US$4.4b impairment charge, while signaling a pivot toward obesity drug programs as well as a larger slate of ...

Patients taking Pfizer’s Vyndaqel and Vyndamax for a progressive, often fatal form of heart failure will not see cheaper ...

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Pfizer shows steady pharmaceutical progress with oncology growth and drug protection strength, shaping healthcare dynamics ...